# Sofosbuvir + Velpatasvir

## Epclusa 400/100mg

##### 臨採

| TAH Drug Code      | [OEPC](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OEPC)                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Indicated for the treatment of chronic hepatitis C virus (HCV) infection in pediatric patients aged 12 years and older, weighing at least 30 kg, and in adult patients with HCV genotypes 1, 2, 3, 4, 5, or 6.                                                                                                                                                                                                                                                                                                           |
| Dosing             | One tablet contains sofosbuvir 400 mg/velpatasvir 100 mg. One tablet once daily for 12 weeks.                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Contraindicated in patients with known hypersensitivity to the active ingredients or any of the listed excipients. Concomitant use with strong P-glycoprotein (P-gp) inducers and strong cytochrome P450 (CYP) inducers: Medications that are strong P-gp and/or strong CYP inducers (such as carbamazepine, phenobarbital, phenytoin, rifampicin, rifabutin, and St. John’s wort) significantly reduce plasma concentrations of sofosbuvir or velpatasvir, which may lead to a decreased therapeutic effect of Epclusa. |
| Adverse Effects    | >10%: Central nervous system: Headache (22%), fatigue (15%) 1% to 10%: Central nervous system: Irritability (?5%), insomnia (5%), depression (1%) Dermatologic: Skin rash (2%) Gastrointestinal: Nausea (9%), increased serum lipase (>3X ULN: 3% to 6%) Neuromuscular & skeletal: Weakness (5%), increased creatine phosphokinase (?10X ULN: 1% to 2%) Frequency not defined: Infection: Reactivation of HBV <1%: postmarketing, and/or case reports: Angioedema                                                        |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| More Info          | [UpToDate](https://www.uptodate.com/contents/sofosbuvir-and-velpatasvir-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                |

